1/15
10:00 am
rare
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
1/13
04:12 pm
rare
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
1/13
11:36 am
rare
Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 39.1% One Year Decline? [Yahoo! Finance]
Low
Report
Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 39.1% One Year Decline? [Yahoo! Finance]
1/13
03:41 am
rare
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Revenue Beat And Gene Therapy Catalysts Update [Yahoo! Finance]
Low
Report
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Revenue Beat And Gene Therapy Catalysts Update [Yahoo! Finance]
1/12
10:33 am
rare
Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery [Yahoo! Finance]
Medium
Report
Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery [Yahoo! Finance]
1/12
08:05 am
rare
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference [Yahoo! Finance]
Medium
Report
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference [Yahoo! Finance]
1/12
07:30 am
rare
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
Medium
Report
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
1/9
03:38 am
rare
Analysts Lower Ultragenyx (RARE) Target but Stay Bullish [Yahoo! Finance]
Medium
Report
Analysts Lower Ultragenyx (RARE) Target but Stay Bullish [Yahoo! Finance]
1/8
10:00 am
rare
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
1/7
04:05 pm
rare
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/6
12:40 pm
rare
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
1/5
12:18 pm
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at HC Wainwright from $80.00 to $60.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at HC Wainwright from $80.00 to $60.00. They now have a "buy" rating on the stock.
1/5
08:12 am
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Guggenheim from $64.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Guggenheim from $64.00 to $52.00. They now have a "buy" rating on the stock.
1/5
03:24 am
rare
Ultragenyx Pharmaceutical (RARE) Advances Gene Therapies, But How Durable Is Its Rare-Disease Strategy? [Yahoo! Finance]
Low
Report
Ultragenyx Pharmaceutical (RARE) Advances Gene Therapies, But How Durable Is Its Rare-Disease Strategy? [Yahoo! Finance]
1/2
12:21 pm
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Bank of America Corporation from $72.00 to $58.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Bank of America Corporation from $72.00 to $58.00. They now have a "buy" rating on the stock.
12/31
07:03 pm
rare
Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? [Yahoo! Finance]
Medium
Report
Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? [Yahoo! Finance]
12/31
07:51 am
rare
Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall [Yahoo! Finance]
Low
Report
Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall [Yahoo! Finance]
12/30
07:07 pm
rare
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today [Yahoo! Finance]
Neutral
Report
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today [Yahoo! Finance]
12/30
04:29 pm
rare
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
12/30
04:10 pm
rare
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) [Yahoo! Finance]
Low
Report
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) [Yahoo! Finance]
12/30
04:05 pm
rare
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
Low
Report
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
12/30
02:24 pm
rare
Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm
Low
Report
Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm
12/30
01:22 pm
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Robert W. Baird from $72.00 to $47.00. They now have an "outperform" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Robert W. Baird from $72.00 to $47.00. They now have an "outperform" rating on the stock.
12/30
01:22 pm
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Leerink Partners from $80.00 to $70.00. They now have an "outperform" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Leerink Partners from $80.00 to $70.00. They now have an "outperform" rating on the stock.
12/30
08:02 am
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Jefferies Financial Group Inc. from $114.00 to $63.00. They now have a "buy" rating on the stock.
High
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Jefferies Financial Group Inc. from $114.00 to $63.00. They now have a "buy" rating on the stock.